Polycystic ovary syndrome: Where are we now?

Journal of Women's Imaging

Volumn 4, Issue 1, 2002, Pages 21-30

  Sadhukhan, Mausumi ^a   Atiomo, William U ^a   Dubbins, Paul ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

Hyperandrogenemia; Insulin Resistance; Oligomenorrhea; Polycystic ovary syndrome; Ultrasound

Indexed keywords

ANDROGEN; ANTIANDROGEN; ANTIESTROGEN; CALCIUM CHANNEL BLOCKING AGENT; CLOMIFENE; CYPROTERONE ACETATE; DEXAMETHASONE; FLUTAMIDE; GESTAGEN; GONADOTROPIN; INSULIN; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

AMENORRHEA; ANOVULATION; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL RESEARCH; CONTROLLED STUDY; DIABETES MELLITUS; ECHOGRAPHY; FEMALE; FEMALE INFERTILITY; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERTENSION; INSULIN RESISTANCE; LAPAROTOMY; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUATION DISORDER; NON INVASIVE MEASUREMENT; OBESITY; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PHILOSOPHY; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0036099014     PISSN: 1084824X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130747-200202000-00007     Document Type: Article

References (87)

1. Polycystic ovary syndrome
2. Amenorrhoea associated with bilateral polycystic ovaries
3. Medical implications of ultrasonically detected polycystic ovaries
4. Multifollicular ovaries: Clinical and endocrine features and response to pulsatile gonadotrophin releasing hormone
5. Transvaginal sonography and abnormal ovarian appearance in menstrual cycle disturbances
6. Polycystic ovary syndrome: The spectrum of disorder in 1741 patients
7. Polycystic ovarian syndrome: The metabolic syndrome comes to gynaecology
8. Definition and significance of polycystic ovaries
9. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach
10. Observations in the polycystic ovary syndrome
11. Ultrasonic tomography of the ovaries
12. The syndromes of insulin resistance and acanthosis nigricans: Insulin receptor disorders in man
13. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease
14. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone levels after reduction of insulin secretion in polycystic ovary syndrome
15. Polycystic ovarian disease: Sonographic spectrum
16. Ovarian volumes measured by ultrasound: Bigger than we think
17. Polycystic ovarian disease: US features in 104 patients
18. How to discriminate between normal and polycystic ovaries: Transvaginal US study
19. Ultrasound assessment of ovarian stroma hypertrophy in hyperandrogenism and ovulation disorders: Visual analysis versus computerized quantification
20. Interrelationship between ultrasonography and biology in the diagnosis of polycystic ovarian disease
21. Ovarian stromal hypertrophy in hyperandrogenic women
22. Accuracy of ultrasound measurements of female pelvic organs
23. Ultrasound criteria in the diagnosis of polycystic ovary syndrome (PCOS)
24. Ultrasonographic patterns of polycystic ovaries: Color Doppler and hormonal correlations
25. The role of color Doppler in the diagnosis of polycystic ovary syndrome
26. Ovarian stromal blood flow in women with polycystic ovaries-a possible new marker for diagnosis?
27. Transvaginal Doppler determination of the ovarian and uterine blood flow characteristics in polycystic ovary disease
28. Doppler parameters of uterine and ovarian stromal blood flow in women with polycystic ovary syndrome and normally ovulating women undergoing controlled ovarian stimulation
29. Polycystic ovaries: Implications of diagnosis with MR Imaging
30. The diagnosis of polycystic ovaries in women with oligo-amenorrhoea: Predictive power of endocrine tests
31. The polycystic ovary syndrome. 1. Pathogenesis
32. Management of polycystic ovary syndrome
33. The polycystic ovary: I. Clinical and histologic features
34. Polycystic ovary syndrome: A changing perspective
35. Heterogeneity of the polycystic ovary syndrome: Clinical, endocrine and ultrasound features in 556 patients
36. Evidence for the role of androgens in follicular maturation
37. Functional studies of aromatase activity in human granulosa cells from normal and polycystic ovaries
38. Circulating and ovarian IGF binding proteins: Potential roles in normo-ovulatory cycles and in polycystic ovarian syndrome
39. Expression of inhibin/activin system messenger ribonucleic acids and proteins in ovarian follicles from women with polycystic ovarian syndrome
40. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) in lean women with and without the polycystic ovary syndrome
41. The plasminogen activator system in women with polycystic ovary syndrome
42. Recurrent early miscarriage and polycystic ovaries
43. An informative protocol for the investigation of recurrent miscarriage: Preliminary experience of 500 consecutive cases
44. Hypersecretion of luteinizing hormones, infertility and miscarriage
45. Does suppressing luteinizing hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial
46. Chronic anovulation caused by peripheral endocrine disorders
47. The effect of weight loss on sex steroid secretion and binding in massively obese women
48. Weight loss is associated with correction of gonadotrophin and sex steroid abnormalities in obese anovulatory women
49. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome
50. Le virilisme pilaire et son association a I'insuffisiance glycolytique (diabete a femmes de barbe)
51. Profound insulin resistance independent of obesity in polycystic ovary syndrome
52. Insulin and C-Peptide secretion in non-obese patients with polycystic ovarian disease
53. Body weight, hyperinsulinaemia and gonadotrophin levels in the polycystic ovarian syndrome: Evidence of two distinct populations
54. Insulin and insulin like growth factor-1 responsiveness in polycystic ovary syndrome
55. Insulin resistance and ovarian dysfunction
56. The relative contributions of hepatic and peripheral tissues to insulin resistance in hyperandrogenic women
57. Hyperinsulinaemia in the polycystic ovary syndrome confirmed with a specific immunoradiometric assay for insulin
58. Effect of chronically elevated androgen or oestrogen on the glucose tolerance test and insulin response in female rhesus monkeys
59. Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion
60. Evidence for insulin resistance in non-obese patients with polycystic ovarian disease
61. Insulin receptor serine phosphorylation may cause insulin resistance in polycystic ovary syndrome (PCOS)
62. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries
63. Insulin stimulates androgen accumulation in incubations of human ovarian stroma and theca
64. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: A long term follow up focusing on natural history and circulating hormones
65. Haemostatic and metabolic variables in women with the polycystic ovary syndrome
66. Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope
67. Pregnancy in infertile PCOD patients: Complications and outcome
68. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20-74 yrs
69. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: A retrospective cohort study
70. The influence of body weight on lipoprotein lipids in patients with polycystic ovary syndrome
71. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome
72. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries
73. Lipid metabolism in women with polycystic ovary syndrome: Possible implications for an increased risk of coronary heart disease
74. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome
75. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women
76. Adenocarcinoma of the endometrium associated with the Stein-Leventhal Syndrome
77. The epidemiology of polycystic ovary syndrome: Prevalence and associated risks
78. Endometrial cancer associated with feminising ovarian tumor and polycystic ovarian disease
79. Surgically induced ovulation in the polycystic ovary syndrome: Wedge resection revisited in the age of laparoscopy
80. Factors affecting the outcome of laparoscopic ovarian drilling for polycystic ovarian syndrome in women with anovulatory infertility
81. Implications of ultrasonically diagnosed polycystic ovaries. I. Correlations with basal hormonal profiles
82. Treatment of hirsutism with the pure antiandrogen flutamide
83. Fatal and nonfatal hepatotoxicity associated with flutamide
84. Hepatotoxicity complicating flutamide treatment of hirsutism
85. The precursors of endometrial carcinoma
86. Metformin therapy is associated with a decrease in plasminogen activator inhibitor-1, lipoprotein (a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome